Becton Dickinson's BD Medical Receives FDA 510(k) Clearance, Commercial Launch of BD UltraSafe PLUS Needle Guard
BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the commercial launch of a new passive needle guard technology, BD UltraSafe PLUS™. The BD UltraSafe PLUS™ Passive Needle Guard has received 510(k) clearance as an anti-needlestick safety device.
This product, in addition to offering needlestick safety in an easy-to-use one-handed device, is enhanced with ergonomic features designed to facilitate comfort and support for healthcare providers and patients. In addition, this safety device is designed to meet increasingly complex biotechnology drug requirements, including higher viscosity.
"We are pleased to offer the new BD UltraSafe PLUS™ Passive Needle Guard which nicely complements our current safety portfolio," said Claude Dartiguelongue, President, BD Medical - Pharmaceutical Systems. "We now have an ergonomic safety device solution for those customers seeking to offer patients the ability to manually control their injection."
The BD UltraSafe PLUS™ Passive Needle Guard provides many advanced features including a robust plunger rod to help support injection of viscous drugs, a larger drug inspection window to improve drug visibility, extended built-in finger flanges and an enhanced plunger head for improved injection support and stability. These ergonomic improvements provide support for all users, including patients with diminished manual dexterity. BD recently conducted a clinical focus group with patients who had reduced dexterity and also suffered from rheumatoid arthritis and multiple sclerosis. Subjects reported that the BD UltraSafe PLUS™ Passive Needle Guard provided ease of use with 100% of injections executed successfully.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.